Earlier this year, we launched a campaign to ensure all eligible patients can access Trodelvy, an exciting new drug that could give some people living with incurable breast cancer the hope of more time.
In this blog, we will look at the work we are doing alongside a coalition of over 50 health organisations, including Cancer Research, Macmillan Cancer Support, and The Health Foundation, to influence the Health and Care Bill, and why it matters for people affected by breast cancer.
In October 2021, we were very disappointed to learn that the National Institute for Health and Care Excellence (NICE) was provisionally unable to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS.
Baroness Delyth Morgan, CEO of Breast Cancer Now, tells us about some of the things she's been part of in her 25 years with the charity, as well as how we are focusing more on people with secondary breast cancer.
We’re committed to improving treatment, care and services for people living with secondary breast cancer, which is why it’s a central part of our new strategy.
Today, we are excited to announce that we have finally secured a long-overdue secondary breast cancer audit in England, delivering on one of the key calls from our Unsurvivors campaign.
In 2017, Jen received a de novo diagnosis of secondary breast cancer after experiencing some unusual symptoms. She tells us about the misconceptions she had about cancer, and how she's working with Breast Cancer Now to campaign for change.